<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03138031</url>
  </required_header>
  <id_info>
    <org_study_id>IS-002-17</org_study_id>
    <nct_id>NCT03138031</nct_id>
  </id_info>
  <brief_title>Percutaneous Ethanol Alcohol Injection for the Large and Unresectable Hepatocellular Carcinoma</brief_title>
  <official_title>Outcome of Percutaneous Ethanol Alcohol Injection (PEI) for the Large and Unresectable Hepatocellular Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The National Ribat University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The National Ribat University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the long-term outcome of percutaneous ethanol alcohol injection (PEI) for the
      large and unresectable hepatocellular carcinoma: single center non-randomized trial.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assessment of the overall (OS); one year; two years and three years` survival rates; the
      disease free survival (DFS) and the tumor response rate in the patients undergoing (PAT or
      PEI) for the large and inoperable hepatocellular carcinoma. This is a prospective non
      randomized trial carried out at the Ribat University Hospital between May 2017 to April 2020.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 1, 2017</start_date>
  <completion_date type="Anticipated">May 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single Group Assignment. Prospective and non-randomized clinical trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival rate</measure>
    <time_frame>3 years</time_frame>
    <description>The percentage of HCC patients who are still alive for three years after they started PEI for HCC.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disease free survival</measure>
    <time_frame>3 years</time_frame>
    <description>Percentage of HCC patients who are alive and well (without a recurrence of their HCC) 3 years after PEI.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major complications` rate</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence of post-procedure Common Terminology Criteria for Adverse Events (CTCAE v4.03) grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tumor response rate</measure>
    <time_frame>3 years</time_frame>
    <description>Mean percentage reduction in the sizes of the patients` tumors</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">15</enrollment>
  <condition>Hepatocellular Carcinoma Non-resectable</condition>
  <arm_group>
    <arm_group_label>Percutaneous Ethanol Injection (PEI)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Those participants receive percutaneous ethanol alcohol injection for the large and unresectable HCC. Absolute alcohol; weekly sessions; under close monitoring; maximum of 30 mls; no anaesthesia needed and a maximum pain score of &quot;8&quot; during the procedure. Postprocedure analgesia may be required.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Percutaneous ethanol alcohol injection</intervention_name>
    <description>Day-case procedure; weekly sessions; uses absolute alcohol; under close monitoring; maximum dose of 30 ml; no anesthesia needed and a maximum pain score of &quot;8&quot; limits the procedure. Post-procedure analgesia may be required.</description>
    <arm_group_label>Percutaneous Ethanol Injection (PEI)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Review and sign informed consent;

          -  Between 15 and 80 years of age at time of trial enrollment;

          -  Documented pathological and/or radiological diagnosis of hepatocellular carcinoma;

          -  Radiologically documented tumor size of &gt; 5 centimeters;

          -  Radiologically documented liver cirrhosis.

        Exclusion Criteria:

          -  American Anesthesia Association (ASA) Class IV or V and/or any

          -  contraindications to general anesthesia;

          -  Uncontrollable ascites;

          -  Deep persistent jaundice;

          -  Hepatic encephalopathy;

          -  Coagulopathy;

          -  Severe thrombocytopenia;

          -  Unable or unwilling to attend follow up visits and examinations;

          -  Other associated surgical procedure;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Murtada A Mohamed, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ribat University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Osama M Elsanousi, MD</last_name>
    <role>Study Chair</role>
    <affiliation>The National Ribat University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Osama M Elsanousi, MD</last_name>
    <phone>+249 1222 29574</phone>
    <email>osamagreen55@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Murtada A Mohamed, MD</last_name>
    <phone>+249 912 395 730</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ribat University Hospital</name>
      <address>
        <city>Khartoum</city>
        <zip>11111</zip>
        <country>Sudan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Sudan</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 30, 2017</study_first_submitted>
  <study_first_submitted_qc>April 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2017</study_first_posted>
  <last_update_submitted>September 24, 2017</last_update_submitted>
  <last_update_submitted_qc>September 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The National Ribat University</investigator_affiliation>
    <investigator_full_name>Osama Mohamed Elsanousi</investigator_full_name>
    <investigator_title>General Surgeon</investigator_title>
  </responsible_party>
  <keyword>Percutaneuos Ethanol alcohol injection</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

